The Clorox Company (CLX) AI Stock Analysis

The Clorox Company manufactures and distributes consumer and professional products across four segments: Health and Wellness, Household, Lifestyle, and International. Its Health and Wellness unit features cleaning and disinfecting solutions including Clorox, Scentiva, Pine-Sol, Liquid-Plumr, and Formula 409, alongside RenewLife and Natural Vitality dietary supplements. The Household segment provides Fresh Step and Scoop Away cat litter, Glad bags and wraps, and Kingsford grilling essentials. Lifestyle offerings include Hidden Valley dressings, Burt's Bees personal care products, and Brita water filtration systems. Internationally, the company sells brands including Ayudin, Poett, and Ever Clean.

Over the past five fiscal years, Clorox experienced a revenue compound annual growth rate of -1.8%, moving from $7.11B in FY2022 to $6.72B in FY2026. Annual revenue declined 5.4% in FY2026, though gross margin stood at 42.3% and operating margin expanded to 24.7%. Net income for FY2026 was $587.0M, down from $810.0M in FY2025, producing diluted EPS of $5.54. In the latest quarter ended June 30, 2026, quarterly revenue decreased 2.0% year-over-year, and quarterly earnings dropped 50.1%. For the trailing twelve months, revenue was $6.72B with a profit margin of 8.7% and EPS of $4.81.

As of June 30, 2026, Clorox held $143.0M in cash and short-term investments against total debt of $5.52B, resulting in net debt of $5.38B and a current ratio of 0.66. Shareholders' equity was $90.0M, resulting in a debt-to-equity ratio of 61.33. In FY2026, operating cash flow was $612.0M and free cash flow was $405.0M. Capital expenditures totaled $207.0M. The company distributed $602.0M in dividends and spent $256.0M on share buybacks, which exceeded its free cash flow.

At $87.09 per share, Clorox has a market cap of $10.53B and an enterprise value of $15.53B. The stock trades at a trailing P/E of 18.1x and a forward P/E of 14.9x, compared to the median of its S&P 500 Consumer Defensive peers of 23.5x trailing and 15.3x forward. Its EV/EBITDA of 13.3x is below the peer median of 14.8x, and its price-to-sales ratio is 1.6x versus the peer median of 1.8x. Over the past year, the stock fell 22.5%, underperforming the SPY gain of 16.8%. Over five years, the stock declined 36.4% while the SPY gained 83.0%.

Clorox pays a quarterly dividend totaling an annualized $5.00 per share, representing a forward dividend yield of 5.74%. The dividend payout ratio stands at 89.9%, backed by 44 consecutive years of dividend payments. Over the past five years, the dividend grew at an annualized rate of 2.5%. The last ex-dividend date was October 28, 2026.

Wall Street analysts carry 1 Strong Buy, 0 Buy, 13 Hold, 2 Sell, and 2 Strong Sell ratings on Clorox. The mean price target of $97.24 indicates upside of 11.6% from the last close of $87.09. For the fiscal year ending June 30, 2027, analysts estimate EPS of $5.72 and revenue of $7.63B. For the following fiscal year, 18 analysts project EPS of $6.16 and revenue of $7.82B. Clorox beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 2, 2026.

This page is an AI-written research summary of The Clorox Company (CLX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CLX income statement, CLX balance sheet, CLX key metrics, CLX analyst forecast, CLX chart. See the CLX stock overview for the latest quote and news.